Summary: Avadel Pharmaceuticals announced its second-quarter results, highlighting the progress of its narcolepsy drug, Lumryz. The company initiated a phase 3 trial for Lumryz in idiopathic hypersomnia and awaits an FDA decision on its use in pediatric narcolepsy. Lumryz, … [Read more...]